object(stdClass)#850 (18) {
["first_name"]=>
string(4) "John"
["last_name"]=>
string(8) "Kirkwood"
["creds"]=>
NULL
["display_email"]=>
string(19) "kirkwoodjm@upmc.edu"
["research_summary"]=>
string(503) "The Kirkwood laboratory is engaged in the study of melanoma immunobiology, and the assessment of multiple new immunomodulators in the context of trials conducted by the Hillman Melanoma Program, and the SPORE in Melanoma and Skin Cancer, as well as the International Melanoma Working Group. The study of predictive and prognostic biomarkers of melanoma complements the studies of molecular inhibitors of melanoma signaling and immunomodulatory agents given alone and in combination with one another.
"
["keywords"]=>
string(81) "Melanoma; immunology; immunotherapy; interferon; cancer vaccines; clinical trials"
["profile_pic"]=>
string(80) "https://s3.amazonaws.com/rmlogix-assets-profilepics/public/img_kirkwoodJohn2.jpg"
["address_1"]=>
string(21) "Hillman Cancer Center"
["address_2"]=>
string(53) "UPCI Research Pavilion 5117 Centre Avenue, Suite 1.32"
["city"]=>
string(10) "Pittsburgh"
["state"]=>
string(2) "PA"
["postal_code"]=>
string(10) "15213-1863"
["phone"]=>
string(12) "412-623-3243"
["current_membership"]=>
string(35) "Cancer Immunology and Immunotherapy"
["member_id"]=>
string(32) "17BC3B85136E2D84960B12D7EB2C3BC7"
["lab_url"]=>
NULL
["department_url"]=>
string(62) "http://www.dept-med.pitt.edu/hemaonc/faculty_info.aspx?fp=4980"
["mybibliography_url"]=>
NULL
}
Hillman Cancer Center UPCI Research Pavilion 5117 Centre Avenue, Suite 1.32 Pittsburgh PA
Phone: 412-623-3243
Research Interests and Keywords:
Melanoma
immunology
immunotherapy
interferon
cancer vaccines
clinical trials
Summary
The Kirkwood laboratory is engaged in the study of melanoma immunobiology, and the assessment of multiple new immunomodulators in the context of trials conducted by the Hillman Melanoma Program, and the SPORE in Melanoma and Skin Cancer, as well as the International Melanoma Working Group. The study of predictive and prognostic biomarkers of melanoma complements the studies of molecular inhibitors of melanoma signaling and immunomodulatory agents given alone and in combination with one another.
